Zanolimumab
From Infogalactic: the planetary knowledge core
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | CD4 |
| Identifiers | |
| CAS Number | 652153-01-0  |
| ATC code | none |
| UNII | HG3L8885M0  |
| KEGG | D06356 |
| Chemical data | |
| Molecular mass | 147 kDa |
| (what is this?) (verify) |
|
Zanolimumab (expected trade name HuMax-CD4[1]) is a human monoclonal antibody and an immunosuppressive drug. It is being developed for the treatment of rheumatoid arthritis, psoriasis, melanoma,[2] cutaneous and peripheral T-cell lymphoma.[3][4] The drug is currently undergoing Phase II trials.[5]
References
- ↑ Genmab initiates Phase II Study with HuMax-CD4
- ↑ http://www.tenxbiopharma.com/development.shtml
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Zanolimumab, American Medical Association.
- ↑ Clinical trial number NCT00042406 for "Trial With HuMax-CD4 in Patients With Rheumatoid Arthritis Failing Treatment With Methotrexate and a TNF-Alpha Blocker" at ClinicalTrials.gov
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
Categories:
- Drugs that are a monoclonal antibody
- Articles without EBI source
- Chemicals that do not have a ChemSpider ID assigned
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Monoclonal antibodies
- Monoclonal antibody stubs
- Antineoplastic and immunomodulating drug stubs
